SRx Health Solutions Received NYSE American Notification Letter Regarding Stockholders' Equity Deficiency
SRx Health Solutions (NYSE American: SRXH) received a notice from NYSE American that it does not meet Section 1003(a)(ii) continued listing standards because its stockholders' equity is below $4.0 million while reporting net losses in three of its four most recent fiscal years.
The company must submit a Plan by November 13, 2025 describing actions to regain compliance by the Plan Period Deadline of July 14, 2026. The notice does not have an immediate effect on listing or trading and does not change SEC reporting obligations.
SRx Health Solutions (NYSE American: SRXH) ha ricevuto una comunicazione da NYSE American che indica che non rispetta i requisiti di quotazione continuata di Sezione 1003(a)(ii) perché il patrimonio netto dei soci è al di sotto di 4,0 milioni di dollari mentre registra perdite nette in tre dei quattro ultimi esercizi fiscali.
L'azienda deve presentare un Piano entro il 13 novembre 2025 descrivendo azioni per riacquistare la conformità entro la scadenza del periodo del piano del 14 luglio 2026. La comunicazione non ha effetto immediato sulla quotazione o sul trading e non modifica gli obblighi di rendicontazione SEC.
SRx Health Solutions (NYSE American: SRXH) recibió un aviso de NYSE American de que no cumple con las normas de cotización continuada de la Sección 1003(a)(ii) porque el patrimonio de los accionistas está por debajo de los $4,0 millones mientras reporta pérdidas netas en tres de los cuatro años fiscales más recientes.
La empresa debe presentar un Plan para el 13 de noviembre de 2025 describiendo las acciones para volver a cumplir antes de la Fecha límite del Período del Plan del 14 de julio de 2026. El aviso no tiene efecto inmediato sobre la cotización y no modifica las obligaciones de presentación ante la SEC.
SRx Health Solutions (NYSE American: SRXH)는 NYSE American으로부터 섹션 1003(a)(ii)의 지속 상장 기준을 충족하지 못한다는 통지를 받았으며, 주주자본이 400만 달러 미만이고 가장 최근 회계연도 중 네 해 중 세 해에서 순손실을 보고하고 있습니다.
회사는 2025년 11월 13일까지 계획서를 제출하고 2026년 7월 14일의 계획 기간 마감일까지 준수를 회복하기 위한 조치를 설명해야 합니다. 이 통지는 상장 또는 거래에 즉시 영향을 미치지 않으며 SEC 보고 의무를 변경하지 않습니다.
SRx Health Solutions (NYSE American: SRXH) a reçu un avis de NYSE American indiquant qu’elle ne satisfait pas aux normes de cotation continue de la section 1003(a)(ii) car les capitaux propres des actionnaires sont inférieurs à 4,0 millions de dollars tout en affichant des pertes nettes dans trois des quatre derniers exercices fiscaux.
L’entreprise doit soumettre un plan d’ici le 13 novembre 2025 décrivant les actions à entreprendre pour retrouver la conformité d’ici la date limite de la période du plan au 14 juillet 2026. L’avis n’a pas d’effet immédiat sur la cotation ou l’échange et ne modifie pas les obligations de reporting auprès de la SEC.
SRx Health Solutions (NYSE American: SRXH) hat von der NYSE American eine Mitteilung erhalten, dass es die fortlaufenden/listing-Standards gemäß Abschnitt 1003(a)(ii) nicht erfüllt, weil das Eigenkapital der Aktionäre unter 4,0 Mio. USD liegt und in drei der vier letzten Geschäftsjahre Nettolose meldet.
Das Unternehmen muss bis zum 13. November 2025 einen Plan einreichen, der beschreibt, welche Maßnahmen ergriffen werden, um die Konformität bis zum Planzeitraum-Deadline vom 14. Juli 2026 wiederherzustellen. Die Mitteilung hat keinen unmittelbaren Einfluss auf die Listung oder den Handel und ändert nicht die SEC-Berichtspflichten.
SRx Health Solutions (NYSE American: SRXH) تلقّت إشعاراً من NYSE American يفيد بأنها لا تستوفي معايير الإدراج المستمر في البند 1003(a)(ii) لأن حقوق المساهمين دون 4.0 مليون دولار بينما تسجل خسائر صافية في ثلاث من أرباعها المالية الأربعة الأخيرة.
يجب على الشركة تقديم خطة بحلول 13 نوفمبر 2025 توضّح الإجراءات اللازمة للامتثال مرة أخرى بحلول الموعد النهائي لفترة الخطة 14 يوليو 2026. لا يترتب على الإشعار أي أثر فوري على الإدراج أو التداول ولا يغير التزامات الإبلاغ لدى هيئة الأوراق المالية والسلع (SEC).
SRx Health Solutions (NYSE American: SRXH) 收到 NYSE American 的通知，称其未符合第1003(a)(ii)条持续上市标准，因为在最近四个财政年度中有三个年度出现净亏损，且股东权益低于400万美元。
公司必须提交一个计划，截止日期为2025年11月13日，以描述在计划期最后期限为2026年7月14日之前重新合规的行动。该通知对上市或交易没有即时影响，也不会改变SEC的披露义务。
- Listing unaffected: notice has no immediate effect on trading or listing
- Clear timeline: must file a compliance plan by Nov 13, 2025
- Compliance window: company has until Jul 14, 2026 to regain compliance
- Equity deficiency: stockholders' equity is below the required $4.0M
- NYSE procedures: subject to Section 1009 continued-listing procedures
- Delisting risk: failure to regain compliance by Jul 14, 2026 may risk delisting
Insights
SRx Health received an NYSE American notice for equity deficiency and must file a remediation plan by
SRx Health Solutions failed the Exchange standard that requires stockholders' equity of
The company must submit a Plan by
Key near-term items to watch: submission of the Plan by
TAMPA, Fla., Oct. 17, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”) today announced it received a notice from the staff of NYSE American LLC (the “Exchange”) that the Company was not in compliance with the Exchange’s continued listing standards under Section 1003(a)(ii) of the NYSE American Company Guide.
Section 1003(a)(ii) requires a listed company to have stockholders’ equity of
SRx Health is subject to the procedures and requirements of Section 1009 of the Company Guide. The Company has until November 13, 2025, to submit a plan (the “Plan”) of actions it has taken or will take to regain compliance with the Exchange’s continued listing standards by July 14, 2026 (“Plan Period Deadline”).
Receipt of the notice from the Exchange has no immediate effect on the listing or trading of SRx Health’s common stock on the Exchange, and does not affect business, operations or reporting requirements with the U.S. Securities and Exchange Commission.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Company Contact:
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer
Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com
FAQ
What did SRXH announce about NYSE American compliance on October 17, 2025?
What deadline does SRXH have to submit a plan to NYSE American?
By when must SRXH regain NYSE continued listing compliance?
Does the NYSE notice affect SRXH trading or SEC reporting immediately?
What NYSE standard did SRXH fail to meet for continued listing?
